Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor.
van Koppen CJ, Verbost PM, van de Lagemaat R, Karstens WJ, Loozen HJ, van Achterberg TA, van Amstel MG, Brands JH, van Doornmalen EJ, Wat J, Mulder SJ, Raafs BC, Verkaik S, Hanssen RG, Timmers CM. van Koppen CJ, et al. Among authors: van achterberg ta. Biochem Pharmacol. 2013 Apr 15;85(8):1162-70. doi: 10.1016/j.bcp.2013.02.001. Epub 2013 Feb 13. Biochem Pharmacol. 2013. PMID: 23415902
Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.
van Koppen CJ, de Gooyer ME, Karstens WJ, Plate R, Conti PG, van Achterberg TA, van Amstel MG, Brands JH, Wat J, Berg RJ, Lane JR, Miltenburg AM, Timmers CM. van Koppen CJ, et al. Among authors: van achterberg ta. Br J Pharmacol. 2012 Apr;165(7):2314-24. doi: 10.1111/j.1476-5381.2011.01709.x. Br J Pharmacol. 2012. PMID: 22014107 Free PMC article.
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, Damming D, Jacobs DC, Rouwette M, Egging DF, van den Dobbelsteen D, Beusker PH, Goedings P, Verheijden GF, Lemmens JM, Timmers M, Dokter WH. van der Lee MM, et al. Among authors: van achterberg ta. Mol Cancer Ther. 2015 Mar;14(3):692-703. doi: 10.1158/1535-7163.MCT-14-0881-T. Epub 2015 Jan 14. Mol Cancer Ther. 2015. PMID: 25589493
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E, Groothuis P, Beusker P, Coumans R, Elgersma R, Menge W, Joosten J, Spijker H, Huijbregts T, de Groot V, Eppink M, de Roo G, Verheijden G, Timmers M. Dokter W, et al. Mol Cancer Ther. 2014 Nov;13(11):2618-29. doi: 10.1158/1535-7163.MCT-14-0040-T. Epub 2014 Sep 4. Mol Cancer Ther. 2014. PMID: 25189543
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.
Ubink R, Dirksen EHC, Rouwette M, Bos ES, Janssen I, Egging DF, Loosveld EM, van Achterberg TA, Berentsen K, van der Lee MMC, Bichat F, Raguin O, van der Vleuten MAJ, Groothuis PG, Dokter WHA. Ubink R, et al. Among authors: van achterberg ta. Mol Cancer Ther. 2018 Nov;17(11):2389-2398. doi: 10.1158/1535-7163.MCT-18-0329. Epub 2018 Aug 9. Mol Cancer Ther. 2018. PMID: 30093567
Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist.
Karstens WFJ, M B P Menge W, Martens G, Op Het Veld SJN, Th H van Eupen J, Demon M, van Achterberg TAE, Arisse-Thijssen MJ, Santegoeds-Lenssen EWH, van der Lee MMC, Ubink R, Arends RJ, Sesink A, Blomenröhr M, Marco Timmers C. Karstens WFJ, et al. Among authors: van achterberg tae. Bioorg Med Chem. 2023 Apr 15;84:117258. doi: 10.1016/j.bmc.2023.117258. Epub 2023 Mar 23. Bioorg Med Chem. 2023. PMID: 37001244 Free article.
23 results